Barriers Eased, U.S. Ramps Up Drug-Plant Inspection Staff In China
This article was originally published in PharmAsia News
Executive Summary
Having ramped up its drug-plant inspection operations in India, U.S. FDA has turned its focus on China where it is increasing local staff, including inspectors, after experiencing several delays.
You may also be interested in...
EU Health Ministers To Deliberate Over Commission’s Pharma Strategy
A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.
Latest Vascepa Lawsuit Plunges Hikma Into Induced Infringement Battle
Hikma has pushed back against a further attempt by Amarin to counter its US generic version of Vascepa, this time via a fresh lawsuit claiming that the generic induces infringement of patents protecting cardiovascular indications for which the brand is approved but which are carved out of the generic label.
EU Approval Of COVID-19 Vaccines Possible In Weeks
The European Medicines Agency will continue working over the Christmas period so that it can complete its assessment of the newly filed marketing applications for BioNTech/Pfizer’s and Moderna’s COVID-19 vaccines as soon possible.
Need a specific report? 1000+ reports available
Buy Reports